KRAS mutation in human CRC cells can privilege the amino-acid consumption from aspartate to asparagine and upregulate asparagine synthetase (ASNS), the enzyme involved in the asparagine biosynthesis (Figure 1a) [49]. This evidence concerns the gene KRAS and colorectal carcinoma.